Browse SLIT3

Summary
SymbolSLIT3
Nameslit guidance ligand 3
Aliases MEGF5; Slit-3; SLIL2; slit (Drosophila) homolog 3; slit homolog 3 (Drosophila); multiple EGF-like domains pr ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF00008 EGF-like domain
PF02210 Laminin G domain
PF13855 Leucine rich repeat
PF01463 Leucine rich repeat C-terminal domain
PF01462 Leucine rich repeat N-terminal domain
Function

May act as molecular guidance cue in cellular migration, and function may be mediated by interaction with roundabout homolog receptors.

> Gene Ontology
 
Biological Process GO:0001554 luteolysis
GO:0001558 regulation of cell growth
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0001960 negative regulation of cytokine-mediated signaling pathway
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008585 female gonad development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0016049 cell growth
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0022602 ovulation cycle process
GO:0022604 regulation of cell morphogenesis
GO:0030308 negative regulation of cell growth
GO:0031960 response to corticosteroid
GO:0035385 Roundabout signaling pathway
GO:0042698 ovulation cycle
GO:0045137 development of primary sexual characteristics
GO:0045926 negative regulation of growth
GO:0046545 development of primary female sexual characteristics
GO:0046660 female sex differentiation
GO:0048511 rhythmic process
GO:0048545 response to steroid hormone
GO:0048588 developmental cell growth
GO:0048608 reproductive structure development
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048675 axon extension
GO:0048846 axon extension involved in axon guidance
GO:0050770 regulation of axonogenesis
GO:0050919 negative chemotaxis
GO:0051384 response to glucocorticoid
GO:0051414 response to cortisol
GO:0060560 developmental growth involved in morphogenesis
GO:0060759 regulation of response to cytokine stimulus
GO:0060761 negative regulation of response to cytokine stimulus
GO:0061364 apoptotic process involved in luteolysis
GO:0061458 reproductive system development
GO:0061564 axon development
GO:0070098 chemokine-mediated signaling pathway
GO:0070099 regulation of chemokine-mediated signaling pathway
GO:0070100 negative regulation of chemokine-mediated signaling pathway
GO:0097485 neuron projection guidance
GO:1901654 response to ketone
GO:1902284 neuron projection extension involved in neuron projection guidance
GO:1902742 apoptotic process involved in development
GO:1990138 neuron projection extension
Molecular Function GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0048495 Roundabout binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG hsa04360 Axon guidance
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-373752: Netrin-1 signaling
Summary
SymbolSLIT3
Nameslit guidance ligand 3
Aliases MEGF5; Slit-3; SLIL2; slit (Drosophila) homolog 3; slit homolog 3 (Drosophila); multiple EGF-like domains pr ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLIT3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSLIT3
Nameslit guidance ligand 3
Aliases MEGF5; Slit-3; SLIL2; slit (Drosophila) homolog 3; slit homolog 3 (Drosophila); multiple EGF-like domains pr ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLIT3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLIT3
Nameslit guidance ligand 3
Aliases MEGF5; Slit-3; SLIL2; slit (Drosophila) homolog 3; slit homolog 3 (Drosophila); multiple EGF-like domains pr ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLIT3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7090.155
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9670.355
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5060.486
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0770.903
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0940.973
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0650.984
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3040.63
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4640.725
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1130.938
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8670.522
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6920.34
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6560.000578
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLIT3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141728.6028.60.0318
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103400400.497
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.78.2-4.50.671
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.78.5-4.80.66
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.323.5-9.20.678
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.5037.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311036.4-36.40.0311
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.53.76.80.393
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLIT3
Nameslit guidance ligand 3
Aliases MEGF5; Slit-3; SLIL2; slit (Drosophila) homolog 3; slit homolog 3 (Drosophila); multiple EGF-like domains pr ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLIT3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLIT3
Nameslit guidance ligand 3
Aliases MEGF5; Slit-3; SLIL2; slit (Drosophila) homolog 3; slit homolog 3 (Drosophila); multiple EGF-like domains pr ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLIT3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLIT3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLIT3
Nameslit guidance ligand 3
Aliases MEGF5; Slit-3; SLIL2; slit (Drosophila) homolog 3; slit homolog 3 (Drosophila); multiple EGF-like domains pr ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLIT3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLIT3
Nameslit guidance ligand 3
Aliases MEGF5; Slit-3; SLIL2; slit (Drosophila) homolog 3; slit homolog 3 (Drosophila); multiple EGF-like domains pr ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLIT3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLIT3
Nameslit guidance ligand 3
Aliases MEGF5; Slit-3; SLIL2; slit (Drosophila) homolog 3; slit homolog 3 (Drosophila); multiple EGF-like domains pr ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLIT3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLIT3
Nameslit guidance ligand 3
Aliases MEGF5; Slit-3; SLIL2; slit (Drosophila) homolog 3; slit homolog 3 (Drosophila); multiple EGF-like domains pr ......
Chromosomal Location5q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLIT3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.